title: Range of retinal diseases potentially treatable by AAV-vectored gene therapy.
abstract: Viable strategies for retinal gene therapy must be designed to cope with the genetic nature of the disease and/or the primary pathologic process responsible for retinal malfunction. For dominant gene defects the aim must be to destroy the presumably toxic gene product, for recessive gene defects the direct approach aims to provide a wild-type copy of the gene to the affected retinal cell type, and for diseases of either complex or unknown genetic origin, more general cell survival strategies that deal with preserving affected retinal cells are often the best and only option. Hence examples of each type of therapy will be briefly discussed in several animal models, including ribozyme therapy for autosomal dominant retinitis pigmentosa in the transgenic P23H opsin rat, beta-PDE gene augmentation therapy for autosomal recessive retinitis pigmentosa in the rd mouse, glial cell-derived neurotrophic factor (GDNF) gene therapy for autosomal dominant RP in the transgenic S334ter opsin rat and pigment epithelial cell-derived neurotrophic factor (PEDF) gene therapy for neovascular retinal disease in rodents. Each employs a recombinant AAV vectored passenger gene controlled by one of several promoters supporting either photoreceptor-specific expression or more general retinal cell expression depending on the therapeutic requirements.
authors.affiliation: Department of Molecular Genetics, University of Florida, Gainesville, FL, USA.
authors.forename: William W
authors.initials: WW
authors.lastname: Hauswirth
authors.forename: Quihong
authors.initials: Q
authors.lastname: Li
authors.forename: Brian
authors.initials: B
authors.lastname: Raisler
authors.forename: Adrian M
authors.initials: AM
authors.lastname: Timmers
authors.forename: Kenneth I
authors.initials: KI
authors.lastname: Berns
authors.forename: John G
authors.initials: JG
authors.lastname: Flannery
authors.forename: Matthew M
authors.initials: MM
authors.lastname: LaVail
authors.forename: Alfred S
authors.initials: AS
authors.lastname: Lewin
mesh_terms: D000818:Animals; D000229:Dependovirus; D005136:Eye Proteins; D005799:Genes, Dominant; D005808:Genes, Recessive; D015316:Genetic Therapy; D005822:Genetic Vectors; D051100:Glial Cell Line-Derived Neurotrophic Factor; D051379:Mice; D009414:Nerve Growth Factors / Q000235:genetics / Q000378:metabolism; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D016337:RNA, Catalytic; D012164:Retinal Diseases / Q000235:genetics / Q000628:therapy*; D015861:Retinal Neovascularization / Q000628:therapy; D015843:Serpins / Q000235:genetics / Q000378:metabolism; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D005136:Eye Proteins; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D011506:Proteins; D016337:RNA, Catalytic; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor; C495040:Gdnf protein, mouse